Research Correspondence

DOI: 10.4244/EIJ-D-24-00158

Temporal trends in characteristics of patients undergoing transcatheter tricuspid edge-to-edge repair for tricuspid regurgitation

Karl-Patrik Kresoja1,2, MD; Lukas Stolz3, MD; Anne Schöber1,2, MD; KarlPhilipp Rommel2, MD; Sebastian Rosch1,2, MD; Florian Schlotter2, MD; Muhammed Gerçek4, MD; Christoph Pauschinger5,6, MD; Wolfgang Rottbauer7, MD; Mohammad Kassar8, MD; Bjoern Goebel9, MD; Paolo Denti10, MD; Tienush Rassaf11, MD; Manuel Barreiro-Perez12, MD; Peter Boekstegers13, MD; Monika Zdanyte14, MD; Marianna Adamo15, MD; Flavien Vincent16, MD, PhD; Philipp Schlegel17, MD; Ralph-Stephan von Bardeleben1, MD; Mirjam G. Wild18, MD; Stefan Toggweiler19, MD; Mathias H. Konstandin17, MD; Eric Van Belle16, MD, PhD; Marco Metra15, MD; Tobias Geisler14, MD; Rodrigo Estévez-Loureiro12, MD; Peter Luedike11, MD; Francesco Maisano10, MD; Philipp Lauten9, MD; Fabien Praz8, MD; Mirjam Kessler7, MD; Andreas Ruck20, MD; Daniel Kalbacher5,6, MD; Volker Rudolph4, MD; Christos Iliadis21, MD; Holger Thiele3, MD; Jörg Hausleiter3,22, MD; Philipp Lurz1, MD, PhD; on behalf of the EuroTR investigators

In the last decade, the management of tricuspid regurgitation (TR) has significantly changed owing to the emergence of novel interventional treatment approaches that have allowed safe and effective treatment of TR. While retrospective studies suggested a survival benefit of interventional TR treatment as compared to patients treated conservatively12, the first randomised clinical trial that compared tricuspid transcatheter edge-to-edge repair (T-TEER) to optimal medical treatment, the TRILUMINATE Pivotal Trial, showed no differences at 1 year with regards to mortality or heart failure hospitalisation, albeit meeting its primary endpoint3. A possible explanation for this discrepancy might be attributable to a change in the characteristics of patients who are referred for T-TEER therapy nowadays, as compared to initial treatment experiences. Therefore, the aim of this study was to evaluate changes in the characteristics of patients referred for T-TEER and investigate their influence on outcomes.

Patients from the European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR) who underwent interventional therapy for symptomatic TR from 2016 until 2022 at 12 European study sites (Germany, Italy, Switzerland, Spain, France, and Sweden) were...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 22
Nov 18, 2024
Volume 20 Number 22
View full issue


Key metrics

Trending articles
310.43

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
166.7

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
92.2

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
76.25

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
35

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
33.9

CLINICAL RESEARCH

10.4244/EIJ-D-17-00381 Oct 11, 2017
Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
Foin N et al
free
33.65

State-of-the-Art

10.4244/EIJ-D-23-00606 Jan 1, 2024
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman R et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved